Even though I groused a bit about the relative delay in getting Rett going, please note that I understand that when you are working with Foundations and govts to provide the money, it will take a bit longer. But the conference yesterday proved that Dr Missling is doing a superb job and has everything lined up to make 2017 spectacular. 3 trials largely paid for with nondilutive foundation financing...genius. the launchpad is ready for this rocket to take off! And he seems to be keeping the FDA informed so the approvals can happen as fast as possible.
We are very fortunate to have Dr. Missling...PhD Chemist, Northwestern Kellogg MBA, CFO and investment banker experience. He is making all the right moves and doing everything well. First class! We could well end 2017 north of $50 a share.
News 
Market Data 
Discover 
